Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men

AIMS/INTRODUCTION: Omarigliptin is a novel, potent, long‐acting oral dipeptidyl peptidase‐4 inhibitor being developed as a once‐weekly (q.w.) treatment for type 2 diabetes mellitus patients, with 25 mg and 12.5 mg tablets recently being approved as market formulations in Japan. MATERIALS AND METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchiya, Saori, Friedman, Evan, Addy, Carol, Wakana, Akira, Tatosian, Daniel, Matsumoto, Yuki, Suzuki, Hideyo, Kauh, Eunkyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217871/
https://www.ncbi.nlm.nih.gov/pubmed/27182005
http://dx.doi.org/10.1111/jdi.12538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217871/
https://www.ncbi.nlm.nih.gov/pubmed/27182005
http://dx.doi.org/10.1111/jdi.12538

Ejemplares similares